VILNIUS UNIVERSITY

FACULTY OF MEDICINE

Institute of Clinical Medicine, Clinic of Cardiac and Vascular Diseases

Hamdi Mohamed, 2020, Group V

INTEGRATED STUDY MASTER'S THESIS

AUTONOMIC NERVOUS SYSTEM AND ARRHYTHMIAS:

A LITERATURE REVIEW

Supervisor: Professor, Dr. Germanas Marinskis

Head of the Clinic: Professor, Dr. Sigita Glaveckaitė

Vilnius, 2026

Hamdi.mohamed@mf.stud.vu.lt

Santrauka

Autonominė nervų sistema ir aritmijos: literatūros apžvalga

Širdies aritmijos yra dažnos ir gali svyruoti nuo lengvų iki sunkių būklių. Pastaraisiais metais autonominė nervų sistema tapo svarbiu veiksniu siekiant suprasti, kaip vystosi aritmijos. Širdies elektrofiziologiją reguliuoja tiek simpatinė, tiek parasimpatinė nervų sistemos. Sutrikus jų pusiausvyrai, gali išsivystyti nenormalūs širdies ritmai.

Šio darbo tikslas yra ištirti, kaip autonominė nervų sistema veikia širdies aritmijų vystymąsi. Šis darbas pagrįstas naratyvine literatūros apžvalga. Aktuali literatūra buvo surinkta atliekant paiešką PubMed ir Google Scholar duomenų bazėse, naudojant raktažodžius, susijusius su širdies ir autonominės nervų sistemos funkcija.

Rezultatai parodė, kad padidėjęs simpatinės nervų sistemos aktyvumas yra susijęs su skilvelinėmis aritmijomis, daugiausia dėl padidėjusio ląstelių jaudrumo ir kalcio perkrovos. Parasimpatinė nervų sistema dažniausiai turi apsauginį poveikį. Tačiau kai kuriais atvejais ji gali prisidėti prie prieširdžių virpėjimo vystymosi, trumpindama refrakterinį periodą. Vidinė širdies nervų sistema yra svarbi reguliuojant šiuos procesus.

Apskritai autonominė nervų sistema atlieka svarbų vaidmenį aritmogenezėje. Geresnis šių mechanizmų supratimas yra svarbus siekiant pagerinti diagnostiką ir gydymą klinikinėje praktikoje.

Raktažodžiai: prieširdžių virpėjimas, autonominė nervų sistema, širdies aritmijos, simpatinis ir parasimpatinis aktyvumas.

Abstract / Summary in English

Autonomic Nervous System and Arrhythmias: A Literature Review

Cardiac arrhythmias are a common and can vary from mild to serious conditions. Recently, the autonomic nervous system has become an important focus in understanding how arrhythmias develop. Cardiac electrophysiology is regulated by both parasympathetic and sympathetic nervous systems. If the balance is disrupted, abnormal heart rhythms can develop. This thesis aims to investigate how the autonomic nervous system influences the development of cardiac arrhythmias. This thesis is based on a narrative literature review; relevant literature was collected through searches in PubMed and Google Scholar databases using keywords related to cardiac and autonomic function.

The findings suggested that elevated sympathetic activity is associated with ventricular arrhythmias primarily through enhanced cellular excitability and calcium overload. The parasympathetic nervous system is usually protective. In some cases, shortened refractory periods may promote the development of atrial fibrilation. The intrinsic cardiac nervous system is important in regulating these processes. In general, the autonomic regulation plays an important role in arrhythmogenesis. Better understanding of these mechanisms is important for improved diagnosis and management in clinical practice.

Keywords: autonomic nervous system, cardiac arrhythmias, atrial fibrillation, sympathetic and parasympathetic activity.

1. Introduction

Cardiac arrhythmias are very common and can sometimes result in serious complications or death. Some arrhythmias are harmless, while others, such as ventricular tachycardia and ventricular fibrillation, can be life-threatening. Their causes are usually complex and involve multiple factors, including structural, electrical, and hormonal components [1-3].

The autonomic nervous system is important for normal cardiac function. It helps to regulate heart rate, electrical signals, and contraction. Normal heart rhythm depends on a balance between the sympathetic and parasympathetic activity. When this balance is disturbed, arrhythmias may occur [1,4-6].

This can happen in situations such as stress, heart disease, or inflammation, which can influence the heart's electrical activity. Higher sympathetic stimulation is associated with ventricular arrhytmias and sudden cardiac death [4,7]. Whereas high parasympathetic activity may cause bradyarrhythmias and atrial fibrillation, often during rest or sleep [6,8]. The heart has its own nervous system [9]. It contains structures such as ganglionated plexi, which are important for regulating cardiac function. These structures have local effects and can influence how arrhythmias develop. Because of this, there is increasing interest in treatments that target the autonomic nervous system [10,11].

Treatments such as beta-blockers work by reducing sympathetic activity. Whereas newer options, including vagal modulation, stellate ganglion blockade, and cardioneuroablation, directly influence the autonomic regulation of the heart [12-14].

1.1 Aims and Objectives

The aim of this thesis is to focus on how the autonomic nervous system contributes to cardiac arrhythmias and effects on cardiac regulation.

Objectives:

- To Explore how autonomic nervous system regulates cardiac activity.
- To assess how altered sympathetic and parasympathetic activity contributes to arrhythmias.

• To review clinical methods used to assess autonomic function.

• To summarize available therapies and highlight potential future development.

1.2 Physiology of the Autonomic Nervous System

The autonomic nervous system regulates cardiac function through interactions between sympathetic, parasympathetic and intrinsic cardiac components. Together these systems work to maintain cardiac stability and allow the heart to adapt to different physiological demands [1–3].

The hypothalamus and brainstem are essential parts of the central autonomic network. They sense signals from the body including blood pressure, oxygen levels and mental stress and respond by modulating heart activity. The brainstem has a special role in the regulation of heart rate and vascular tone by reflex processes, such as the baroreceptor reflex [15].

These systems have opposite effects on cardiac function. The sympathetic nervous system activates β-adrenergic receptors which raise heart rate, conduction velocity and contractility. This leads in increased calcium entry into the cardiac cells and increased myocardial contraction and excitability [5,16]. The vagus nerve is prominent in the parasympathetic nervous system. It slows conduction and decreases heart rate, notably at the atrioventricular (AV) node. This is achieved by activation of muscarinic receptors which lower cyclic AMP levels and enhance potassium efflux, resulting in hyperpolarization of heart cells [5,15].

Normal cardiac rhythm depends on a balance between the two systems. Small disruptions of this equilibrium can change cardiac electrophysiology and enhance the propensity for arrhythmias (Figure 1) [2,3]. The heart has its own neurological system, apart from central control. This system is composed of ganglionated structures (plexi) situated in the walls of the atrium and surrounding the pulmonary veins. These structures can modulate cardiac activity and independently alter the heart's response to autonomic input [9-11].

The intrinsic cardiac nervous system plays a part in the initiation and development of arrhythmias. It may cause local changes in conduction and refractoriness that can promote

abnormal electrical activity. Thus, it has become a critical focus for newly developed treatment techniques [2,6].



Figure 1. *Overview of autonomic control of the heart.*

This figure shows how the autonomic nervous system regulates cardiac activity through interactions between sympathetic and parasympathetic systems. Sympathetic activation increases heart rate, conduction, and contractility, whereas the parasympathetic system, primarily via the vagus nerve, reduces heart rate and atrioventricular conduction. These effects are regulated by the central autonomic network and act on key structures within the heart.

Adapted from [4,9,15].

1.2.1 Central Autonomic Network

The brain's control center for the heart is called the central autonomic network (CAN). This network controls how the heart and blood vessels function by integrating signals from nerves, hormones, and the environment [15].

The network consists of several brain regions, including the hypothalamus, brainstem, amygdala, and insular cortex. These regions process information about the body and emotional state. They then adjust cardiac function to maintain balance in the body. The brainstem contains important centers that sense blood pressure and chemical changes in the blood. This information is used to regulate sympathetic and parasympathetic activity [15].

The hypothalamus acts as a higher-level center that controls responses to stress, temperature, and metabolic demands [15].

If this network is disrupted, for example by disease, chronic stress, or inflammation, its control may be impaired. This can disturb the balance between autonomic systems and increase the risk of arrhythmias [4,15].

1.2.2 Cellular and Molecular Bases

At the cellular level, autonomic cardiac regulation depends on neurotransmitters and receptor-dependent signaling pathways. Sympathetic effects are mainly mediated by norepinephrine acting on β1-adrenergic receptors on cardiomyocytes. The activation of these receptors activates the enzyme adenylate cyclase, increasing cyclic AMP (cAMP) synthesis and activating protein kinase A (PKA). This process increases calcium entry through L-type calcium channels. As a result, the heart becomes more excitable, and heart rate, contractility, and conduction increase [5,16].

Parasympathetic activity works differently. It uses acetylcholine, which acts on M2 receptors.
This lowers cAMP levels and increases potassium flow through GIRK channels. As a result, pacemaker cells become more stable, and heart rate and atrioventricular conduction decrease [5,15].

The balance between these antagonistic signaling pathways is critical for maintaining a normal heart rhythm. Dysregulation at the receptor or intracellular signaling level can significantly affect electrophysiological stability and predispose to arrhythmogenesis [2,3].

1.2.3 Electrophysiological Regulation of Ion Channels

The autonomic control of cardiac electrophysiology is closely linked to the regulation of ion channels involved in the generation and propagation of action potentials. In sinoatrial node pacemaker cells, spontaneous depolarization depends mainly on the funny current (If), carried by HCN channels [17].

Phase 4 depolarization in these cells is strongly affected by the autonomic nervous system. This links ion channel activity directly to heart rate control. Sympathetic stimulation increases If current and calcium channel activity. This makes phase 4 depolarization faster and increases heart rate [5,16,17].

Parasympathetic stimulation has the opposite effect. It reduces If current and increases potassium conductance. This slows pacemaker activity [5,17,18].

Autonomic input also affects atrial and ventricular myocytes. It modulates sodium (Na^+), calcium (Ca^{2+}), and potassium (K^+) channels. This influences action potential duration, conduction velocity, and refractory periods [3,19].

When this regulation is disturbed, ion channel activity becomes more uneven. This can lead to dispersion of repolarization and contribute to arrhythmogenesis. These electrical abnormalities provide an important substrate for arrhythmias, particularly in patients with structural heart disease or neural remodeling. These mechanisms are summarized in Figure 2 [16,19,20].

These electrical disturbances may contribute to both atrial and ventricular arrhythmias.Their effects can become stronger in condition such as heart disease, ischemia, or autonomic imbalance. Understandning these mechanisms may help improve future treatment strategies.



Figure 2. *Cardiac action potential and ion channel activity.*
This figure shows the cardiac action potential, which consists of five phases (0–4), each characterized by the movement of ions across the cell membrane. Phase 0 represents rapid depolarization due to sodium influx through fast Na^+ channels. Phase 1 reflects initial repolarization. Phase 2, known as the plateau phase, is primarily mediated by calcium influx via L-type Ca^{2+} channels balanced by potassium efflux. During phase 3, increased potassium efflux leads to repolarization, while phase 4 represents the resting membrane potential maintained mainly by potassium currents.

Ionic mechanism is essential to maintain proper cardiac electrophysiology and play a major role in the development of arrhythmias.

Adapted from [16,20].

1.3 Epidemiology of Cardiac Arrhythmias

Cardiac arrhythmias are a major burden on global health. Among these, atrial fibrillation (AF) is considered the most common sustained arrhythmia. Its prevalence increases with age affecting around 1–2% of the general population and up to 10% of individuals over 80 years old [18,21]. This highlights the growing clinical importance of AF in an aging population. Age-related structural changes, particularly atrial fibrosis, act as the arrhythmogenic substrate, while autonomic imbalance functions mainly as a trigger.

Autonomic imbalance contributes significantly to arrhythmias development, particularly in individuals with underlying cardiovascular disease. Increased sympathetic activity is commonly observed in disorders such as heart failure, ischemic heart disease, and chronic stress, which are all linked to a higher risk of ventricular arrhythmias and sudden cardiac death [2,6].

Parasympathetic effects are also clinically important, especially among younger patients without structural heart disease, in whom vagally induced atrial fibrillation and bradyarrhythmias may develop [11]. Autonomic dysfunction is likewise frequently observed metabolic disorder, such as diabetes mellitus, and has been linked to increased risk of cardiovascular morbidity and mortality [22,23].

In conclusion, the involvement of autonomic dysfunction with cardiovascular disease demonstrates the significance of the autonomic nervous system in the epidemiology of cardiac arrhythmias [2,6].

1.4 Risk Factors and Clinical Significance

Autonomic dysfunction is associated with cardiac arrhythmias, and clinical variables can modify this relationship. Age is one of the most important risk factors, as aging is associated with structural cardiac changes, reduced autonomic flexibility, and an increased susceptibility to atrial fibrillation and conduction abnormalities [9,20].

Another important factor is structural heart disease. Heart failure, ischemic heart disease, cardiomyopathy, and valvular disease may alter the myocardial substrate and increase the susceptibility to arrhythmias. In these individuals, sympathetic activity is typically elevated as a compensatory response to reduced cardiac performance. However, persistent sympathetic stimulation may promote myocardial excitability, calcium overload, and electrical instability, thereby increasing the risk of ventricular arrhythmias and sudden cardiac death [2,16].

Metabolic disorders are also clinically relevant, particularly diabetes mellitus. Diabetic autonomic neuropathy can affect both sympathetic and parasympathetic control of the heart. This may result in decreased heart rate variability, resting tachycardia, reduced baroreflex sensitivity, and an increased risk of silent ischemia and arrhythmias.

Autonomic dysfunction in diabetes is therefore considered an important marker of cardiovascular risk [22,23].

Autonomic balance may also be influenced by exogenous and lifestyle-related factors. Emotional stress, sleep deprivation, excessive alcohol intake, use of stimulants, and intense physical exertion may all increase sympathetic tone and trigger tachyarrhythmias in susceptible individuals. In contrast, some individuals develop vagally mediated atrial fibrillation or bradyarrhythmias during periods of increased vagal tone, such as at rest, during sleep, or after meals [2,8].

Inflammation and systemic illness can also contribute to arrhythmias. These conditions may affect both autonomic regulation and cardiac electrophysiology. Acute infections, fever, electrolyte disturbances, and inflammatory heart diseases such as myocarditis may increase the risk of arrhythmias, particularly in patients with underlying cardiovascular disease [15].

From a clinical perspective, it is important to identify these risk factors. Some autonomically mediated arrhythmias require specific treatment strategies. Evaluating comorbid conditions, triggers, symptoms, and cardiac structure can improve both diagnosis and management. Understanding how autonomic dysfunction affects the heart is essential for risk assessment and appropriate treatment selection [17,24].

2. Literature Review Research and Methodology

This thesis is a narrative literature review of the involvement of the autonomic nervous system in cardiac arrhythmias. The aim was to collate and summarize existing information in a clear way.

Relevant publications were searched electronically in PubMed and Google Scholar. We selected these resources because they offer access to a series of medical and scientific studies. Keywords were selected to cover different sections of the topic; they included “autonomic nervous system,” “sympathetic activation,” “parasympathetic activity,” “arrhythmogenesis,” “atrial fibrillation,” “ventricular arrhythmias,” and “cardiac electrophysiology.” The keywords were used alone and in various combinations to identify relevant studies.

Only peer-reviewed articles written in English were included. Most studies were from the last 10 years to reflect current understanding. Some earlier studies were added to help clarify the core ideas.

Studies were selected based on relevance and quality. Both clinical and experimental research were included because they provide relevant insights. We removed articles that were not linked to cardiac electrophysiology or autonomic control. Basic language tools were used to check grammar and improve clarity. The content and scientific interpretation were developed by the author.

A total of 100-120 abstracts were reviewed. The focus of the course was on the contribution of each study to the knowledge of autonomic processes involved in arrhythmias.

Selected research was categorized under topics including sympathetic activation, parasympathetic effects, autonomic imbalance, and clinical consequences. The papers were analyzed to identify similatities, discrepancies, and gaps in the literature.

As this is a narrative review, no formal statistical analysis was undertaken. This approach provides a broader overview of the subject but also has limitations, including a risk of selection bias and potential influence of the author's interpretation.

3. Results

3.1 Sympathetic Nervous System and Arrhythmogenesis

The autonomic nervous system is divided into two major parts: the sympathetic and parasympathetic systems. They act on the heart in different ways.

The sympathetic system increases heart rate, conduction, and contractility through βadrenergic receptors. The parasympathetic system has the opposite effect, decreasing heart rate and conduction, particularly through the vagus nerve [2,17].

These systems are usually balanced, which helps to maintain a stable heart rhythm. Disturbance of this equilibrium increases the likelihood of arrhythmias [2].

Studies have shown that increased sympathetic activity is a significant factor in arrhythmogenesis. This leads to the release of norepinephrine, which binds to β-adrenergic receptors in the heart. This increases cAMP levels as well as calcium influx and makes the heart more excitable (see Figure 3) [5,16].

These alterations can cause abnormal electrical activity, such as early and delayed afterdepolarizations (EADs and DADs). Sympathetic activation can also shorten the action potential duration and enhance spatial heterogeneity of repolarization, which can favor reentry [11,18,20].

Both clinical and experimental studies support a link between increased sympathetic activity and ventricular arrhythmias. This is particularly evident in conditions such as ischemic heart disease, heart failure, and severe stress. High catecholamine levels are also associated with ventricular tachycardia, ventricular fibrillation, and sudden cardiac death [2,16,25-27]. Overall, increased sympathetic activity can initiate and perpetuate severe arrhythmias.



Figure 3. *Sympathetic activation and arrhythmogenesis.*

This figure shows how sympathetic activation stimulates β_1-adrenergic receptors in the heart, leading to increased heart rate, conduction, and automaticity. These effects enhance myocardial excitability and promote the initiation and maintenance of cardiac arrhythmias.

Adapted from [2,5,16]

3.2 Parasympathetic Nervous System and Arrhythmogenesis

The parasympathetic nervous system mainly influences the heart through the vagus nerve. Acetylcholine is released from the vagus nerve, which acts on muscarinic M2 receptors. This results in reduced intracellular cyclic AMP levels and activation of potassium currents, which hyperpolarize cardiac pacemaker cells [5,15]. Parasympathetic activity reduces sinus node firing, slows atrioventricular conduction, and lowers atrial excitability (see Figure 4) [4,6,28]. In many cases, this helps maintain a stable heart rhythm and protects against arrhythmias [1].

Parasympathetic influence is often most prominent during rest and sleep, when vagal tone is naturally higher. This physiological variation explains why some arrhythmias, particularly vagally mediated atrial fibrillation, tend to occur at night or during periods of relaxation. In contrast to sympathetic activation, which is usually linked to stress or physical activity, parasympathetic effects are more closely related to recovery states [1].

However, the role of parasympathetic activity in arrhythmias remains complex. Increased vagal tone can shorten the atrial refractory period and create heterogeneity in refractoriness. This can lead to re-entry and may trigger atrial fibrillation [1,8]. This is especially seen in vagally mediated atrial fibrillation, which often occurs at rest or during sleep, particularly in younger patients without structural heart disease [1].

Excessive parasympathetic activity can also affect conduction in the atrioventricular node, which may result in bradyarrhythmias such as sinus node dysfunction and atrioventricular block [1,2]. These conditions are often reversible but can sometimes require clinical intervention if symptoms are significant.

In summary, these findings suggest a dual role of parasympathetic activity, with effects that are context-dependent in clinical situations [1,2]. While it generally has a protective role, under certain conditions it may contribute to arrhythmia development.



Figure 4. *Parasympathetic (vagal) regulation of cardiac electrophysiology.*

This figure shows how parasympathetic stimulation via the vagus nerve releases acetylcholine (ACh), which activates muscarinic receptors on cardiomyocytes. This signaling pathway reduces intracellular cAMP levels and modulates ion channel activity, leading to decreased heart rate, reduced conduction, and altered excitability. These electrophysiological effects may contribute to arrhythmogenesis under specific conditions.

Adapted from [9,11].

3.3 Role of the Cardiac Ganglionated Plexi

The heart has its own neural system, called the intrinsic cardiac nervous system. Within this system ganglionated plexi (GP) have a significant role. These structures are mainly located around the atria, pulmonary veins and the atrioventricular junction. They help integrate signals from both the sympathetic and parasympathetic nerve systems and affect how the heart reacts [4,9,11].

Stimulation of these plexi has been shown to trigger abnormal electrical activity. This is especially seen in the pulmonary veins which are a common source of atrial fibrillation

[10,11]. The activation of these plexi may modify atrial refractoriness and conduction, which may increase the risk of re-entry (see Figure 5) [8,10].

Clinical investigations indicate an involvement of ganglionated plexi not only in the initiation but also in the maintenance of atrial fibrillation. This has made them a target for therapy. Techniques like cardioneuroablation attempt to modulate these neuronal circuits and have demonstrated promising outcomes in selected individuals [12-14].

In conclusion, the intrinsic cardiac nervous system is not a passive system. Rather, it has important role in the active modulation of heart rhythm and may play a role in arrhythmogenesis [4,9].



Figure 5. *Anatomical distribution of cardiac ganglionated plexi.*

This figure illustrates where ganglionated plexi are located in specific regions around the atria, particularly near the pulmonary veins and atrioventricular junction. These structures acts as integration centers for autonomic input and play a key role in the initiation and maintenance of atrial fibrillation.

Adapted from [9,11].

3.4 Neural Remodeling and Electrophysiological Changes

Neural remodeling is an important process linking chronic autonomic imbalance to the initiation and maintenance of cardiac arrhythmias. The disorder is related to anatomical and functional alterations of the cardiac autonomic nervous system. These alteration are associated with electrophysiological property changes and enhanced arrhythmogenic susceptibility (see Figure 6) [4,21,29].

Long-term sympathetic activity, which is frequently seen in heart failure, ischemic heart disease, and chronic stress, leads to anatomical alterations of cardiac innervation. These changes include more nerve growth and uneven nerve signals. This can cause differences in electrical activity in the heart. It may lead to conduction problems and changes in repolarization [19,21,30].

Remodeling of parasympathetic nerves may also occur, especially in ganglionated plexi in the atrial myocardium. An increased parasympathetic tone can reduce atrial effective refractory time and increase spatial heterogeneity, which may lead to the formation of reentry circuits. This process is particularly important in vagally driven atrial fibrillation [1,11,25].

In addition to brain changes, electrical remodeling occurs at the cellular level. Changes in ion channel expression, calcium handling, and action potential length impact conduction velocity and myocardial excitability. These changes predispose one to triggered activity such as early and delayed afterdepolarizations [16,18,19,21].

Inflammation and fibrosis also help the remodeling process. Chronic inflammation conditions cause interstitial fibrosis that impairs normal conduction routes and promotes re-entry processes. The combination of neuronal and structural remodeling results in a highly arrhythmogenic substrate, especially in individuals with chronic cardiovascular disease [21,31]. Crucially, brain remodeling is a dynamic and potentially reversible process. Reinnervation may take place over time after operations such as sympathetic denervation or cardioneuroablation and may lead to recurrence of arrhythmia. This highlights the need for long-term monitoring and better approaches for sustained autonomic regulation [14,24,32].



Figure 6. *Autonomic neural remodeling in cardiac arrhythmias.*

This figure illustrates the neural remodeling involves structural and functional changes in cardiac autonomic innervation, including sympathetic denervation and subsequent reinnervation. These processes lead to heterogeneous autonomic input and contribute to electrophysiological instability, thereby promoting the initiation and maintenance of arrhythmias.

Adapted from [33]. Description based on [4,9,21].

3.5 Autonomic Imbalance in Specific Arrhythmias (AF, VT, Bradyarrhythmias)

Autonomic imbalance has a significant influence on several types of cardiac arrhythmias. The primary mechanism depends on the type of arrhythmia [2,34].

Both sympathetic and parasympathetic activity affect atrial fibrillation. Sympathetic activity increases intracellular calcium and enhances cardiac excitability. Parasympathetic activity shortens the atrial refractory period and may favor re-entry. Together, these effects increase the likelihood of atrial fibrillation, as illustrated in Figure 7 [12,14].

Ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) are generally associated with increased sympathetic activity. High levels of catecholamines may increase automaticity, promote afterdepolarizations, and disrupt repolarization. This is

most observed in patients with structural heart disease [1,8,18,19]. Bradyarrhythmias are typically related to increased parasympathetic activity. Elevated vagal tone may slow sinus node activity and atrioventricular conduction, which may lead to sinus bradycardia or atrioventricular block. In some cases, ganglionated plexi may also be involved [1,2,11].

In conclusion, autonomic balance appears to influence both the type and severity of cardiac arrhythmias [2,35].



***Figure** 7. Mechanisms of atrial fibrillation in autonomic imbalance.*

This figure shows how autonomic imbalance contributes to atrial fibrillation through increased myocardial excitability and shortened refractory periods. Ectopic activity originating from the pulmonary veins, together with re-entry mechanisms within the atria, leads to disorganized electrical activity, as illustrated in this figure.

Adapted from [14,18]. Description based on [8, 10, 19].

3.6 Mechanisms of Re-entry and Triggered Activity

Two major mechanisms in cardiac arrhythmias are re-entry and triggered activity (see Figure 8). Both are influenced by the autonomic nervous system and can occur in atrial and ventricular arrhythmias [11,15].

Re-entry occurs when an electrical impulse travels in a loop and re-excites the same area of tissue. Three conditions are needed: heterogeneous conduction, unidirectional block, and slow conduction. These conditions can be promoted by autonomic imbalance.Sympathetic activity shortens the action potential and increases differences in conduction.Parasympathetic activity decreases refractory time. Together, these changes increase the risk of re-entry, especially in atrial fibrillation [1,8,21].

Triggered activity is caused by abnormal depolarizations that occur after an action potential. These are called early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs). EADs occur during repolarization, while DADs occur after repolarization. DADs are often related to increased intracellular calcium, mainly due to sympathetic activity [16,18,19].

Sympathetic stimulation increases calcium entry and release. This increases the risk of DADs and triggered beats. It is especially important in ventricular arrhythmias, for example during stress, ischemia, or heart failure [16,21,26]. Parasympathetic activity can also contribute by reducing refractory time and increasing electrical differences, which favors re-entry [1,8].

Another mechanism is abnormal automaticity. This occurs when non-pacemaker cells start to generate their own impulses. It can happen during sympathetic activation or ischemia and may trigger arrhythmias [2,17].

Autonomic imbalance affects all of these mechanisms by influencing ion channels, calcium handling, and conduction. This increases the risk of arrhythmias and helps explain how normal heart rhythm becomes abnormal [2,21].



Figure 8. *Mechanism of re-entry in cardiac arrhythmias. The figure shows how an electrical impulse may continuously circulate in a loop due to unidirectional block and slow conduction. Initially, the conduction is blocked in one pathway while it continues through another pathway. When the blocked pathway recovers, the impulse can re-enter and travel in a circle. This leads to repeated activation of the same tissue and can cause a sustained arrhythmia. This mechanism is commonly seen in atrial fibrillation and tachycardias.*

Adapted from [2,17,21].

3.7 Clinical Manifestations of Autonomic Arrhythmias

The symptoms of autonomic induced arrhythmias can differ between patients. They depend on the type of arrhythmia, the level of autonomic instability, and underlying heart disease. Symptoms may range from mild to severe [2,24]. The most common presentation is palpitations. Patients often describe them as fast, irregular, or pounding heartbeats. They may start suddenly. They can be triggered by stress or physical activity but may also occur at rest or during sleep [1,2,24]. Syncope and presyncope are important symptoms.

They are more common in bradyarrhythmias or reflex-mediated arrhythmias. Increased vagal tone can suppress the sinus node or atrioventricular conduction. This can reduce cerebral blood flow and lead to fainting [2,22,36].

In patients with sympathetic-driven arrhythmias, such as ventricular tachycardia, symptoms may be more severe. These include chest discomfort, dyspnea, dizziness, or hemodynamic instability. These episodes may be triggered by stress, physical activity, or acute illness [2,26,27].

Vagally mediated arrhythmias, such as atrial fibrillation, are more common at rest, after meals, or during sleep. These patients are often younger and may not have structural heart disease, which can make diagnosis more difficult [1,8]. Other symptoms include fatigue, reduced exercise tolerance, and anxiety. These are often related to changes in heart rate and autonomic control [22,23]. Some arrhythmias may be asymptomatic and are detected incidentally on ECG [21,24].

Overall, it is important to recognize these patterns. They can help guide diagnosis and treatment. Identifying triggers and symptoms may provide important information about the underlying mechanism [1,2,21].

3.7.1 Triggers and Patterns

Autonomic arrhythmias often appear in certain situations. In most cases, they are linked to how the balance between sympathetic and parasympathetic activity shifts [2,5].

Sympathetic activity tends to rise during stress or physical effort. When this happens, the heart becomes more excitable. This can trigger faster rhythms such as atrial fibrillation or ventricular arrhythmias, especially in people who already have heart disease [2,16,26].

Parasympathetic activity is more active at rest, during sleep, or after meals. In these situations, vagally mediated arrhythmias may occur. Atrial fibrillation related to vagal tone is often seen at night or early in the morning. Some patients also report symptoms after eating [1,8]. Exercise has mixed effects on the autonomic system. Light to moderate activity is usually protective. However, intense exercise can act as a trigger in some individuals. Athletes often have higher vagal tone, which may contribute to bradyarrhythmias or vagally mediated atrial fibrillation [2,6,18].

4. Diagnosis

Diagnosis is mainly based on clinical evaluation and monitoring [22,23]. ECG recordings are essential, and in some cases autonomic testing may be helpful [22,24].

Since autonomic activity varies over time, it is important to look at changes in heart rate and rhythm rather than a single measurement. For this purpose, Holter monitoring is considered a “gold standard” for evaluating autonomic function. It allows for the analysis of established parameters such as SDNN and RMSSD, which provide a detailed picture of the patient's autonomic tone over an extended period [22, 23].

4.1 Autonomic Function Tests

Autonomic function tests are used to evaluate the balance between sympathetic and parasympathetic activity. They can give an idea of how the autonomic nervous system is involved in arrhythmias [22,23].

Heart Rate Variability (HRV) and Holter Monitoring are commonly used non-invasive methods, providing indirect information about autonomic tone. While short-term HRV can be assessed in the clinic, Holter monitoring is considered a "gold standard" for evaluating autonomic function in a real-world setting. By recording the heart’s activity over 24 hours or longer, it allows for the calculation of established time-domain parameters:

- SDNN (standard deviation of NN intervals), which reflects overall autonomic activity [22,23,].
- RMSSD (root mean square of successive differences), which is a primary marker of parasympathetic (vagal) tone [22,23,].

In general, higher HRV is linked to more parasympathetic activity, while low HRV (low SDNN/RMSSD) is often seen when sympathetic activity dominates and has been associated with a higher arrhythmia risk [22,23,37,38]. Other Diagnostic Tests The tilt-table test is used to see how the body reacts to changes in position. It is mainly used when vagal reactions, orthostatic intolerance, or reflex syncope are suspected [36,39].

Baroreflex sensitivity (BRS) reflects how heart rate changes in response to blood pressure.

Lower BRS has been linked to worse outcomes and a higher risk of serious arrhythmias [5,40,41]. Other simple tests include the Valsalva maneuver and deep breathing, which mainly assess parasympathetic function by observing heart rate responses [22,42].

Overall, these tests do not provide a complete picture on their own, but they can help indicate autonomic dysfunction, as shown in Figures 9 and 10 [22,23].



Figure 9. *Heart rate variability (HRV) and tilt-table test used to assess autonomic function.*

This figure illustrates two commonly used methods for assessing autonomic function.HRV (Heart Rate Variability): Heart rate variability refers to the variation in time between consecutive heartbeats. It is a non-invasive measure of autonomic function. Higher HRV is associated with increased parasympathetic activity, while lower HRV reflects sympathetic dominance and has been linked to higher cardiovascular risk.

Tilt-table test: The tilt-table test evaluates autonomic responses to changes in body position. The patient is moved from supine to upright while heart rate and blood pressure are monitored. It is mainly used in the investigation of syncope, especially when reflex or orthostatic causes are suspected.

Adapted from Neurobit Technologies and [37, 39]. Description based on [23].



Figure 10. *Baroreceptor reflex and blood pressure regulation.*

This figure shows how the body responds to a sudden drop in blood pressure. Baroreceptors detect reduced stretch in the vessel walls and send signals to the brain. This leads to increased sympathetic activity and reduced parasympathetic activity. As a result, heart rate and contractility increase, and blood vessels constrict, helping restore blood pressure toward normal levels.

Adapted from [5,40,41].

4.2 ECG, Holter, and Electrophysiological Evaluation

Electrocardiography is important for detecting arrhythmias related to autonomic activity. A standard 12-lead ECG can show rhythm changes, conduction abnormalities, and signs of autonomic imbalance, such as changes in heart rate and PR or QT intervals [2,21,24].

Holter monitoring records cardiac rhythm over 24 to 48 hours or longer. It helps detect brief episodes of arrhythmias and daily variations in heart rhythm. This is useful for identifying patterns, such as arrhythmias during sleep or stress [22,23,43].

Electrophysiological (EP) studies are used in selected patients [2,21]. Some newer electrophysiological and neuromodulatory approaches, including low-level vagal stimulation, have also been investigated in atrial fibrillation [44]. They help assess conduction pathways, locate arrhythmia sources, and evaluate how the autonomic system affects the heart. These tests provide detailed information about arrhythmia mechanisms, as shown in Figure 11 [2,21].



Figure 11. *Electrocardiographic evaluation of cardiac rhythm.*

The conventional 12-lead electrocardiogram (ECG) is a basic diagnostic tool for evaluating heart rhythm, conduction abnormalities, and electrical activity. It provides important information for detecting and characterizing arrhythmias.

Adapted from [2,21].

4.3 Differential Diagnosis

Other cardiac and non-cardiac diseases can resemble autonomically generated arrhythmias and should be assessed [24,25]. Structural heart disease, electrolyte derangements, and endocrine illness such as thyroid disease can all influence cardiac excitability and produce arrhythmias [2,23,24]. Drug-related reasons should be explored as well, especially those that change autonomic tone [21].

Exclude major electrical diseases such as long QT syndrome and Brugada syndrome [24,45]. Other inflammatory disorders such as myocarditis need to be explored [15,46]. A systematic approach is crucial to separating autonomic causes from other disorders and directing therapy [23,24].

4.4 Imaging in Autonomic Disorders

Imaging can be informative in the assessment of autonomically mediated arrhythmias [23]. It is useful for identifying structural changes that may interact with autonomic dysfunction. Cardiac MRI may identify fibrosis and scar tissue, while echocardiography helps evaluate heart function and structural disease [23,46]. Imaging does not directly reveal autonomic activity but can help identify arrhythmia risk [23,24].

4.5 Clinical Work-Up and Evaluation

Arrhythmias related to the autonomic nervous system are assessed with a structured clinical approach [23,24]. The autonomic effects can change over time and depend on triggers, so careful evaluation is important [2,21].

The first step is taking a good medical history. This includes symptoms like palpitations, dizziness, or syncope, and how they start, how long they last, and how often they occur [21]. It is also important to ask about triggers such as stress, exercise, sleep, or food [2,24]. The physical examination may show signs of heart disease or other conditions. Autonomic function can be checked by assesing heart rate and blood pressure in different positions [21,22]. ECG is an important part of the assessment. A standard 12-lead ECG can show changes in rhythm, conduction, and repolarization [23,24].

5. Management

The goal of treatment is to restore balance in the autonomic nervous system, keep the heart rhythm stable, and prevent new episodes [2,23]. Treatment depends on whether the main problem is increased sympathetic or parasympathetic activity [2,17].

Treatment options include medications, neuromodulation, or procedures that affect the autonomic system [12-14,44]. The choice depends on the type of arrhythmia, the cause, and the patient [23,24]. In many cases, a combination of treatments is needed [23].

5.1 Pharmacologic modulation (β-blockers, anticholinergic treatment).

Pharmacological treatment are an important part of management. They aim to correct the imbalance between sympathetic and parasympathetic activity [2,23].

β-blockers are commonly used, especially when sympathetic activity is high. They block β1 receptors. This reduces cAMP and calcium entry. As a result, heart rate decreases, conduction slows, and excitability is reduced. They can also reduce early and delayed afterdepolarizations. In clinical practice, β-blockers are used to reduce ventricular arrhythmias, decrease the risk of sudden cardiac death, and help to control heart rate in atrial fibrillation [16,24,47].

Anticholinergic drugs, such as atropine, are mainly used in acute situations. They block M2 receptors and reduce parasympathetic activity. This increases heart rate and improves conduction. They are useful in symptomatic bradyarrhythmias and AV block [23,24].

Calcium channel blockers, such as verapamil and diltiazem, can also be used. They reduce calcium entry in nodal tissue. This slows conduction and lowers heart rate. They are often used for rate control in supraventricular arrhythmias [23,47].

Some antiarrhythmic drugs also affect autonomic tone or cardiac electrophysiology. The choice depends on the type of arrhythmia [24,45].

In general, pharmacological therapy is the first step. It is widely used and often effective. However, it may not be enough in patients with more severe or resistant arrhythmias [23,24].

5.2 Neuromodulation Techniques (Stellate Ganglion Block, Vagal Stimulation)

Neuromodulation is used when pharmocological treatment is not enough. The aim is to influence the autonomic nervous system directly [12,13,44].

One method is vagal nerve stimulation. It increases parasympathetic activity and can help stabilize heart rhythm [13,14]. A promising non-invasive form is Low-Level Tragus Stimulation (LLTS), which targets the auricular branch of the vagus nerve to increase heart rate variability and reduce the burden of atrial fibrillation [44,47]. LLTS has gained

interest because it is non-invasive and generally well tolerated. Current studies have shown a promising results, but still more research is needed to better understand its long-term effects and possible role in arrhythmia treatment.

Another option is stellate ganglion block. It reduces sympathetic activity and may reduce the risk of ventricular arrhythmias, especially in patients with severe or recurrent episodes (see Figure 12) [12, 48].

In severe cases, cardiac denervation is a more invasive procedure for selected patients with life-threatening arrhythmias. It reduces sympathetic input to the heart and can help prevent arrhythmia episodes [35,49].

These treatments are usually considered when standard therapy is not enough. The choice depends on the type of arrhythmia and the patient's condition [23,24,50].



Figure 12. *Vagal modulation of cardiac function.*

Parasympathetic stimulation through the vagus nerve lowers heart rate, slows atrioventricular conduction, and reduces myocardial excitability. These effects help regulate cardiac rhythm and may prevent some supraventricular arrhythmias.

Adapted from [1,8,10].

5.3 Cardioneuroablation

Cardioneuroablation is a catheter-based technique that targets the heart's autonomic system. It may be used in patients with vagally mediated atrial fibrillation, functional bradyarrhythmias, and vasovagal syncope [14,51]. The procedure targets ganglionated plexi located in the atria. This reduces excessive parasympathetic activity and helps restore autonomic balance [14].

Early studies have shown positive results. These include fewer arrhythmias, better heart rate control, and symptom relief in selected patients [30]. However, long-term results are still being studied, and careful patient selection is important (see Figure 13) [24,51].



Figure 13. *Common targets for cardioneuroablation.*

This figure shows the main locations in the heart where cardioneuroablation is performed, known as ganglionated plexi (GP). These nerve clusters are mainly located around the pulmonary veins and specific areas of the atria. Using a catheter-based approach, these regions are targeted to reduce excessive parasympathetic activity, which may help stabilize cardiac rhythm.

Adapted from [14, 30,31].

5.4 Comparison of Treatment Strategies

Treatment strategies for autonomi mediated arrhythmias differ in how they work and how they used in clinically [23,24]. In most cases, drug treatment is the primary choice, especially in individuals with elevated sympathetic activity [2,23]. It may not be enough, however, in individuals with refractory arrhythmias [24,50].

Interventional therapies such as catheter ablation and neuromodulation are more direct in targeting the issue. They can alleviate symptoms but are more invasive and need careful patient selection [12-14,35]. In certain individuals, the combination of pharmacological therapy with interventional treatment may improve long term outcomes [23,24,50].

5.5 Evidence from Clinical Studies

Today, there is evidence that autonomic modulation may help reduce arrhythmias in some patients [23,24]. However, the level of evidence differs between therapies.

The most established approach is drug treatment, especially β-blockers. Studies have shown that they reduce heart rate, sympathetic activity, and the risk of ventricular arrhythmias and sudden cardiac death, particularly in heart failure and ischemic heart disease [16,24,46].

Stellate ganglion block and cardiac sympathetic denervation have shown positive effects in patients with refractory ventricular arrhythmias, such as electrical storm. They can reduce arrhythmia episodes and ICD shocks [48-50]. However, the effect may not last, and longterm results are still unclear [49,50].

Cardioneuroablation is a newer technique. Early studies suggest that some patients have fewer symptoms and better control of heart rate [30]. However, the effect may not be sustained over time, and the lack of long-term clinical benefits are still unclear. Other approaches, such as vagal stimulation, have shown mixed results and are not commonly used [13,44].

Overall, autonomic modulation may benefit some patients, especially when standard treatment is not effective [23,24]. More research is needed to understand long-term effects and improve management [23].

Table 1 Summary of therapeutic approaches targeting autonomic modulation in arrhythmia management

Treatment	Mechanism	Clinical Use	Evidence	Limitations
Beta-blockers	↓ sympathetic activity, ↓ HR, ↓ excitability	First-line (AF, VT, HF)	Strong evidence	Side effects, incomplete control
Anticholinergics	↓ vagal tone	Acute bradyarrhythmias	Limited	Short-term use
Stellate ganglion block	↓ sympathetic outflow	Electrical storm, refractory VT	Moderate	Temporary effect
Cardioneuroablation	Ablation of ganglionated plexi	Vagal AF, bradyarrhythmias	Emerging	Limited longterm data

Adapted from [12-14,23,24,48].

5.6 Lifestyle and Non-pharmacological Management

Lifestyle changes are important in treating autonomic mediated arrhythmias. They are often used together with medication or procedures. The goal is to reduce symptoms and prevent triggers [2,23].

Stress can trigger arrhythmias. It increases sympathetic activity. Simple methods like relaxation, breathing exercises, or mindfulness can help [2,50]. Sleep is very important. Poor sleep or sleep apnea can increase the risk of arrhythmias.

Treating sleep problems, for example, with CPAP, can help [23,46]. Exercise can be helpful, but it depends on intensity. Moderate exercise is usually good. It improves heart health. Very intense exercise can trigger arrhythmias in some people. Exercise should be adapted to the patient [2,23].

Diet also matters. Alcohol, caffeine, and stimulants can trigger arrhythmias. It is often recommended to reduce these. Drinking enough fluids is also important [2,23].

Other diseases should be treated as well. Conditions like high blood pressure, diabetes, obesity, and heart failure can increase the risk of arrhythmias. Good control of these conditions is important [23,24,46].

Patient education is important. Patients should understand their symptoms and triggers. This helps them manage their condition better. Keeping a symptom diary can sometimes help [21,23].

Overall, lifestyle changes are an important part of treatment. Together with other treatments, they can reduce symptoms and improve long-term results [23,24].

6. Emerging and Advanced Therapies

New and advanced therapies targeting the autonomic nervous system are being explored as treatment options for patients with refractory or complex arrhythmias. These approaches aim to provide more precise control of autonomic pathways beyond standard drug and interventional treatments [52,53,54].

The relationship between the autonomic nervous system and cardiac arrhythmias is complex and multifactorial [2,17]. In clinical practice, both structural and functional factors interact with autonomic regulation to influence cardiac electrophysiology [44,55]. Understanding these interactions is important for identifying underlying causes and improving patient management [23,25].

In addition, variations in autonomic tone over time may contribute to differences in arrhythmia presentation and progression. This highlights the importance of considering both dynamic and patient-specific factors when evaluating autonomically mediated arrhythmias [21,50,56].

6.1 Sympathetic Denervation (e.g., Stellate Ganglion Ablation)

Sympathetic denervation is an advanced treatment that aims to reduce excessive sympathetic input to the heart. It is usually done by stellate ganglion block or surgical cardiac sympathetic denervation. These methods interrupt sympathetic pathways from the cervical and upper thoracic ganglia [12,48,57].

These treatments are mostly used in patients with severe ventricular arrhythmias, such as electrical storm or refractory ventricular tachycardia. This is often seen in patients with structural heart disease, including ischemic cardiomyopathy or heart failure. In these patients, high sympathetic activity plays an important role in arrhythmias [49,58,59].

By reducing sympathetic outflow, denervation lowers myocardial excitability, reduces catecholamine-related triggered activity, and decreases differences in repolarization. This may help to stabilize cardiac rhythm and reduce arrhythmia episodes [35,52,60].

Surgical cardiac sympathetic denervation has a more long-lasting effect. It works by removing or disrupting sympathetic ganglia, especially the left stellate ganglion and thoracic ganglia (T2–T4) [49,61].

Stellate ganglion block is usually performed as a percutaneous procedure, often with ultrasound guidance to improve safety [12,48,62,63]. It can give rapid but often temporary control of arrhythmias and may suppress ventricular arrhythmias in selected patients (see Figure 14) [64,65].

Clinical studies suggest that sympathetic denervation can reduce ventricular arrhythmias and ICD shocks in selected high-risk patients. It is often used as an additional treatment when drug therapy and catheter ablation are not enough [49,50,52].

However, there are some limitations. The response can vary, and there are procedural risks. Reinnervation may also occur over time. Therefore, careful patient selection and follow-up are important [32, 56].



Figure 14. *Stellate ganglion block for arrhythmia control.*

This figure shows an ultrasound-guided injection targeting the stellate ganglion (C6–T1). By blocking this structure, sympathetic activity to the heart is reduced, which may help suppress ventricular arrhythmias.

[Adapted from [12,48,49]

6.2 Novel Interventions and Experimental Approaches

Experimental therapies are currently being studied to improve autonomic regulation of arrhythmias. These include renal denervation to reduce sympathetic activity and vagal nerve stimulation to increase parasympathetic activity [13,44,66].

There have also been advances in catheter-based treatments, targeted therapies, and bioelectronic medicine. Early results are promising, but more studies are needed to better understand longterm effects, safety, and which patients may benefit most [14,51,67].

6.3 Future Perspectives in Modulation of Autonomics

Further studies may help us better understand and manage arrhythmias. Wearable devices and continuous monitoring are newer technologies that can provide real-time assessment of heart rate and autonomic function. This may help detect abnormalities earlier and predict the risk of arrhythmias [68].

Artificial intelligence and machine are increasingly being used in arrhytmia research [69,70]. They may help to identify large amounts of data and find patterns that are difficult to recognize which may improve diagnosis and support more individualized therapies.

Neuromodulation therapies such as cardioneuroablation and sympathetic denervation need further research. More studies are needed to understand long-term effects and to identify the right patients. Molecular and cellular research may also lead to new targeted therapies, focusing on specific parts of the autonomic system [71].

In the future, treatment will likely become more individualized and based on new technologies and a better understanding of underlying mechanisms.

7. Long-Term Outcomes and Follow-Up

Long-term outcomes in patients with autonomically mediated arrhythmias vary between individuals. They depend on the underlying cause, the degree of autonomic imbalance, and how well the treatment works. Recurrence is still common, especially in patients with persistent autonomic dysfunction. Follow-up is important to evaluate treatment effects and detect recurrence. Follow up should be individualized and focus on symptom changes and rhythm control over time [2,23,34].

Patients respond differently to treatment. Some benefit from targeted autonomic therapies, while others may need a combined approach, especially if structural heart disease is present. Autonomic function may change over time. Reinnervation after treatment can occur and may lead to recurrence. For this reason long-term follow up is important [50,72].

Overall, management of these patients requires an individualized approach, with attention to long-term outcomes, recurrence risk, and ongoing follow-up.

8. Discussion

The long-term prognosis of patients with autonomically mediated arrhythmias varies and depends on the underlying cause, the degree of autonomic imbalance, and the effectiveness of treatment. Although many patients improve initially, recurrence remains common [2,23,24].

A persistent autonomic imbalance after treatment may contribute to recurrent arrhythmias. This may explain why arrhythmias return and the need for long-term follow-up [2,23]. Patients also respond differently to treatment. Some benefit from therapies targeting the autonomic nervous system, while others, especially those with structural heart disease—require a more combined approach [2,23,24,46].

Autonomic function may change over time, which adds complexity. Reinnervation after ablation or denervation may lead to recurrence [32,72]. This shows the importance of ongoing clinical assessment and adapting treatment strategies over time.

Patient involvement is also important. Understanding symptoms and triggers can improve self-management. Lifestyle modifications and adherence to treatment may further improve outcomes [2,23,50].

From a clinical perspective, it is important to determine whether the arrhythmia is predominantly sympathetically or vagally mediated. This distinction can guide treatment decisions, such as the use of β-blockers in sympathetically mediated arrhythmias or consideration of autonomic-targeted therapies in vagally mediated conditions [2,23,24].

In conclusion, autonomically mediated arrhythmias are complex and require an individualized approach. Future guidelines should better integrate autonomic modulation into standard care, particularly as therapies such as neuromodulation and cardioneuroablation continue to evolve [73].

8.1 Limitations of the Study

This thesis is based on a narrative literature review, which has some limitations. Since it is not a systematic review, the selection of studies is not fully structured, and some relevant studies may have been missed.

Another limitation is that evidence for newer autonomic therapies remains limited. For example, cardioneuroablation is mainly supported by small observational studies, and there is a lack of large randomized controlled trials. Therefore, its long-term effectiveness and safety are not yet fully established.

In addition, the included studies are heterogeneous. They vary in study design, patient populations, methods used to assess autonomic function, and duration of follow-up. This makes it difficult to compare results directly and draw firm conclusions.

Accurate assessment of autonomic function also remains challenging. Common tests, such as heart rate variability, baroreflex sensitivity, and tilt-table testing, provide indirect estimates rather than exact measurements. Their results may also be influenced by factors such as age, medication, stress, sleep, and underlying disease.

Research in this field rapidly grows, with new researches emerging continuously. Therefore, some aspects of this thesis may become outdated over time.

Despite these limitations, this thesis summarizes current knowledge about the role of the autonomic nervous system in cardiac arrhythmias and highlights key mechanisms and clinical aspects.

8.2 Clinical Implications

In clinical practice, it is important to understand how the autonomic nervous system affects arrhythmias. This can help with both diagnosis and treatment.

Identifying triggers and patterns can help explain the underlying cause of the arrhythmia and make it easier to choose the right treatment. For example, it is important to know if the arrhythmia is vagal or sympathetic. Patients with vagally mediated atrial fibrillation may benefit more from lifestyle changes and treatments such as cardioneuroablation,

while patients with sympathetically driven arrhythmias often respond better to β-blockers and stress reduction [2,23,24,51].

Assessing the autonomic system can also help with risk evaluation. Tests such as heart rate variability and other autonomic assessments can provide useful information and help identify patients at higher risk of serious arrhythmias [18,19].

Treatments targeting the autonomic system are becoming more common. These approaches can help patients who do not respond to standard therapy and highlight the importance of addressing both the electrical and autonomic components of arrhythmias [74].

9. Conclusion

In conclusion, the autonomic nervous system has an important role in the development of cardiac arrhythmias. It affects both heart function and electrical activity. Normal cardiac rhythm depends on a balance between sympathetic and parasympathetic activity. If this balance is disturbed, arrhythmias can occur.

This study shows that arrhythmias are not only caused by electrical problems in the heart, but also by changes in autonomic control. For this reason, treatment should consider both the electrical system and the autonomic nervous system. Standard treatments are still important, but newer approaches may help in more complex cases. However, there are still challenges to overcome. We do not yet fully understand the long-term results, and patients respond differently to treatment. In addition, changes in autonomic function over time may contribute to arrhythmia recurrence.

Future research should focus on better risk assessment and more personalized treatment strategies. This may help identify which patients benefit most from therapies targeting the autonomic system [2,23,24,74]. Overall, including the autonomic system in clinical practice may lead to more individualized and effective care for patients with arrhythmias.

References

1. Coumel P. Cardiac arrhythmias and the autonomic nervous system. J Cardiovasc Electrophysiol. 1993;4(3):338-55.

2. Zipes DP, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. 7th ed. Philadelphia: Elsevier; 2018.

3. Verrier RL, Antzelevitch C. Autonomic aspects of arrhythmogenesis. Curr Opin Cardiol. 2004;19(1):2-11.

4. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014;114(6):1004-21.

5. Schwartz PJ, De Ferrari GM. Sympathetic–parasympathetic interaction in health and disease. Heart Fail Rev. 2011;16(2):101-7.

6. Billman GE. Cardiac autonomic nervous system and arrhythmogenesis. Auton Neurosci. 2006;131(1-2):1-8.

7. Schwartz PJ. The autonomic nervous system and sudden cardiac death. Eur Heart J. 1998;19(Suppl F): F72-80.

8. Chen PS, et al. Role of the autonomic nervous system in atrial fibrillation. Circulation. 2014;129(8): e6-9.

9. Armour JA. Potential clinical relevance of the “little brain” on the mammalian heart. Exp Physiol. 2008;93(2):165-76.

10. Chen PS, et al. Mechanisms of atrial fibrillation: neural influences. J Cardiovasc Electrophysiol. 2001;12(3): S12-7.

11. Po SS, et al. Localization of ganglionated plexi in the atria. Circulation. 2009;119(4):521-7.

12. Doytchinova A, et al. Stellate ganglion nerve activity and ventricular arrhythmias. J Am Coll Cardiol. 2017;70(1):128-39.

13. Schwartz PJ, et al. Vagal nerve stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res. 1991;68(5):1471-81.

14. Pappone C, et al. Pulmonary vein denervation enhances atrial fibrillation ablation outcomes. J Am Coll Cardiol. 2004;43(12):2314-22.

15. Benarroch EE. The central autonomic network: functional organization and clinical correlations. Neurology. 1993;43(5):938-44.

16. Bers DM. Cardiac excitation–contraction coupling. Nature. 2002;415(6868):198-205.

17. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106(3):434-46.

18. Nattel S. New ideas about atrial fibrillation. Nature. 2002;415(6868):219-26.

19. Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation. J Clin Invest. 2010;120(3):745-54.

20. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev. 2005;85(4):1205-53.

21. Weiss JN, Qu Z, Shivkumar K. The electrophysiology of arrhythmias. Circulation. 2017;135(24):2326-41.

22. Malik M, Camm AJ. Heart rate variability. Clin Cardiol. 1990;13(8):570-6.

23. Task Force of the ESC and NASPE. Heart rate variability: standards of measurement. Circulation. 1996;93(5):1043-65.

24. Priori SG, et al. ESC Guidelines for the management of patients with ventricular arrhythmias. Eur Heart J. 2015;36(41):2793-867.

25. Sinnaeve PR, et al. The importance of atrial fibrillation as a prognostic factor in patients with acute myocardial infarction. Eur Heart J. 2012;33(3):344-52.

26. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976;294(21):1165-70.

27. Podrid PJ, et al. Catecholamines and arrhythmias. Prog Cardiovasc Dis. 1990;32(4):265-
79.

28. Kupari M, et al. Relation of heart rate variability to indices of left ventricular hypertrophy and function. Am J Cardiol. 1993;72(11):831-5.

29. Cao JM, et al. Nerve sprouting and sudden cardiac death. Circ Res. 2000;86(7):816-21.

30. Chen PS, et al. Sympathetic remodeling and cardiac arrhythmias. J Cardiovasc Electrophysiol. 2007;18(1):117-21.

31. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802-9.

32. He B, et al. Neural reinnervation after catheter ablation: implications for arrhythmia recurrence. J Cardiovasc Electrophysiol. 2007;18(11):1196-1201.

33. Stavrakis S, et al. Low-level vagus nerve stimulation in humans. JACC Clin Electrophysiol. 2020;6(3):249-57.

34. Kasanuki H, et al. Role of the autonomic nervous system in sudden cardiac death. Am J Cardiol. 1997;80(9A):118F-23F.

35. Vaseghi M, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias. J Am Coll Cardiol. 2014;64(22):2429-30.

36. Brignole M, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-1948.

37. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59(4):255-62.

38. Bigger JT, et al. Correlations among time and frequency domain measures of heart rate variability. Circulation. 1992;85(1):164-71.

39. Kenny RA, et al. Head-up tilt: a new test for investigating unexplained syncope. Lancet. 1986;1(8494):1352-5.

40. La Rovere MT, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality (ATRAMI). Lancet. 1998;351(9101):478-84.

41. ATRAMI Investigators. Autonomic tone and reflexes after myocardial infarction. Circulation. 1999;99(2):224-30.

42. Ewing DJ, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985;8(5):491-8.

43. Kleiger RE, et al. Time domain measures of heart rate variability. Cardiol Clin. 1992;10(3):487-98.

44. Stavrakis S, Jackman WM, et al. Low-level transcutaneous vagus nerve stimulation suppresses atrial fibrillation. J Am Coll Cardiol. 2015;65(9):867-75.

45. Schwartz PJ. The long QT syndrome. Curr Probl Cardiol. 1997;22(6):297-351.

46. Caforio AL, et al. Current state of knowledge on myocarditis: a focus on MRI. Eur Heart J. 2013;34(33):2636-48.

47. Kirchhof P, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.

48. Bourque K, et al. Stellate ganglion block for refractory ventricular arrhythmias: suppression of electrical storm. Case Rep Cardiol. 2016; 2016:8971675.

49. Vaseghi M, et al. Long-term outcomes of cardiac sympathetic denervation in patients with ventricular tachycardia. J Am Coll Cardiol. 2017;69(25):3070-80.

50. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-9.

51. Pachon JC, et al. Cardioneuroablation: new approach for treating vagal-induced bradyarrhythmias and atrial fibrillation. Europace. 2005;7(1):1-13.

52. Valenza G, et al. Advanced technologies for autonomic nervous system monitoring and modulation. Front Physiol. 2019; 10:112.

53. Hasan W. Autonomic innervation of the heart: role in health and disease. Auton Neurosci. 2016; 199:11-22.

54. D'Silva A, et al. Gene therapy and the autonomic nervous system in heart rhythm management. J Interv Card Electrophysiol. 2021;61(1):11-23.

55. Rizzo S, et al. Structural and neural interaction in the arrhythmogenic heart. Cardiovasc Res. 2020;116(9):1649-60.

56. Goldberger JJ, et al. Autonomic nervous system and cardiac arrhythmias: personalized medicine. Circulation. 2019;140(20):1611-3.

57. Ajijola OA, et al. Extracardiac neural remodeling in humans with ventricular arrhythmias. Circulation. 2015;132(4):230-40.

58. Nademanee K, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation. Circulation. 2011;123(12):1270-9.

59. Driver S, et al. Stellate ganglion blockade for refractory ventricular arrhythmias. Europace. 2021;23(4):594-601.

60. Yuan K, et al. Electrophysiological effects of sympathetic denervation on the heart. Front Pharmacol. 2022; 13:845123.

61. Waldmann V, et al. Surgical cardiac sympathetic denervation in patients with inherited channelopathies. JACC Clin Electrophysiol. 2019;5(4):411-21.

62. Cleveland Clinic. Stellate ganglion block [Internet]. Available from: https://my.clevelandclinic.org/health/treatments/17507-stellate-ganglion-block (accessed 2026 Apr 30).

63. Gaba S, et al. Ultrasound-guided stellate ganglion block: an updated review of anatomy and techniques. Pain Physician. 2023;26(1): E11-22.

64. Tian Y, et al. The effect of left stellate ganglion block on cardiac autonomic function. J Clin Monit Comput. 2021;35(3):567-75.

65. Hayase J, et al. Stellate ganglion blockade for refractory ventricular arrhythmias. JACC Case Rep. 2022;4(10):588-92.

66. Esler MD, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension. Lancet. 2010;376(9756):1903-9.

67. Ukena C, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction. Am J Hypertens. 2013;26(9):1164-70.

68. Iacoviello M, et al. Bioelectronic medicine in cardiovascular diseases: a focus on autonomic modulation. Trends Cardiovasc Med. 2022;32(7):423-31.

69. Zucker IH, et al. The role of the sympathetic nervous system in heart failure: new therapeutic targets. Circ Res. 2016;118(1):34-53.

70. Nyns EC, et al. Optogenetic termination of ventricular arrhythmias. Nat Commun. 2017;8(1):1524.

71. Hulot JS, et al. Gene therapy for heart failure and arrhythmias. Cardiovasc Res. 2016;111(4):307-21.

72. Prasad A, et al. Nerve growth factor and cardiac sympathetic remodeling. J Am Coll Cardiol. 2011;58(5):549-54.

73. Sassi R, et al. Advances in heart rate variability signal analysis: artificial intelligence approaches. IEEE Rev Biomed Eng. 2021; 14:122-35.

74. Goldberger JJ, et al. Relationship of heart rate variability to the autonomic nervous system: new insights from big data. Circulation. 2020;142(10):915-17.